Leerink downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a $2 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics price target lowered to $17 from $40 at Piper Sandler
- Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial of bexotegrast
- Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Cheat Sheet
- Positive Outlook on Pliant Therapeutics Despite Trial Uncertainty
- Hold Rating on Pliant Therapeutics Amid Safety Concerns in BEACON-IPF Trial